International health advocates are criticizing Bayer after the German pharmaceutical giant announced it may contest a decision that could make life-saving medication available to cancer patients in the developing world.
In a landmark case, the Indian Patent Office issued a compulsory license in India to a generic drug manufacturer, effectively ending Bayer’s monopoly on a drug used to treat kidney and liver cancer.
According to international humanitarian organization Doctors Without Borders, competition from the generic version will bring the price of the ...
continue reading...